Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Fiorentino Edward reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings, Inc. reported that director Edward Fiorentino received a grant of common stock as board compensation. On April 1, 2026, he was issued 2,124 shares under the non-employee director compensation policy in lieu of a $14,124.60 quarterly cash retainer at $6.65 per share. Following this award, he directly holds 73,487 shares of Senseonics common stock.
Steven Edelman reported acquisition or exercise transactions in this Form 4 filing.
Senseonics Holdings director Steven Edelman received a stock grant as part of his board compensation. He was awarded 1,936 shares of common stock, valued at $12,874.40 based on a $6.65 closing price on April 1, 2026, in lieu of quarterly cash retainer fees.
Following this grant, Edelman directly holds 78,829 shares of Senseonics common stock. This was a compensation-related award rather than an open-market purchase or sale, and no derivative securities are reported in this filing.
Senseonics Holdings, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held on May 20, 2026. The record date is March 26, 2026, when 41,795,466 shares were outstanding. Key proposals include the election of three Class I directors (Timothy T. Goodnow, Francine R. Kaufman and Sharon Larkin), an advisory say-on-pay vote and a say-on-frequency vote, ratification of KPMG LLP as independent auditors, approval to increase authorized common shares from 70,000,000 to 140,000,000, and approval of the Senseonics Holdings, Inc. 2026 Equity Incentive Plan.
The proxy discloses reserve and capitalization context as of the record date: 41,795,466 shares outstanding, aggregate reserved shares of 14,233,357 across plans and warrants, and 13,971,177 unissued, unreserved shares. The company reported $15.8 million gross profit for the twelve months ended December 31, 2025 and an accumulated deficit of $1 billion. The Board recommends a vote FOR all proposals.
Senseonics Holdings, Inc. director Douglas A. Roeder purchased additional company stock in the open market. On March 13, 2026, he bought 17,500 shares of common stock at $5.73 per share. Following this transaction, his direct ownership increased to 119,731 shares, reflecting a meaningful personal investment in the company.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow made an open-market purchase of common stock. On March 13, 2026, he bought 17,225 shares at a weighted average price of $5.79 per share, bringing his direct ownership to 651,243 shares after the transaction.
Senseonics Holdings, Inc. has entered into a series of Local Asset Purchase Agreements with Ascensia Diabetes Care to acquire additional assets tied to commercial Eversense CGM activities in Italy, Germany, Spain and Sweden. These European Asset Purchases build on a prior master asset purchase agreement covering U.S. rights.
At each European closing, expected on or before June 30, 2026 subject to customary conditions and required consents, Senseonics will pay cash based on the net book value of the related assets and assumed liabilities. A separate Transition Services Agreement will have Ascensia provide logistics, IT, finance, regulatory and other support in the European territories, generally through dates up to June 30, 2026, to help ensure an orderly handover and continuity of Eversense operations.
Senseonics Holdings, Inc. files its Annual Report describing a diabetes-focused medical technology business built around Eversense, a long-term implantable continuous glucose monitoring system. The company highlights FDA approval and U.S. launch of its 365-day Eversense 365 system in 2024.
The report details a major shift in commercial strategy as Senseonics acquires Eversense commercial assets from Ascensia, regains U.S. marketing rights, and from January 1, 2026 is entitled to 100% of Eversense revenues in key European territories. The company outlines pivotal trials, upcoming Gemini and Freedom sensor platforms, extensive patent protection through 2049, and notes that 41,770,466 shares of common stock were outstanding as of February 20, 2026.
Senseonics Holdings, Inc. reported strong growth for the fourth quarter and full year 2025 while continuing to invest heavily in commercialization of its Eversense 365 long-term CGM system. Q4 revenue rose to $14.3 million, up from $8.3 million, driven mainly by U.S. sales.
For 2025, total revenue increased to $35.3 million from $22.5 million, and gross profit improved sharply to $15.8 million from $0.5 million as one-time transition charges rolled off and margins on the 365-day product improved. The annual net loss narrowed to $69.1 million, or $1.66 per share, from $78.6 million, reflecting better gross profit offset by higher selling, general and administrative expenses as the company took Eversense commercialization and distribution back in-house and ramped direct-to-consumer marketing.
Cash, cash equivalents and investments totaled $94.3 million with indebtedness of $35.3 million at December 31, 2025. For 2026, Senseonics expects global net revenue of $58–$62 million, implying 65–76% growth, and targets gross margins of about 50% as it completes the transition from Ascensia and expands Eversense 365 globally and into automated insulin delivery integrations.
Senseonics Holdings, Inc. furnished a current report to share business updates and preliminary, unaudited financial information for the year ended December 31, 2025. The company did this by issuing a press release, which is attached as Exhibit 99.1, and referenced in the report for details on preliminary revenue and year-end cash, cash equivalents and restricted cash levels.
The company notes that these figures are estimates, have not been reviewed or audited, and may change when its 2025 financial statements are finalized and audited. The report emphasizes that statements about expected fourth quarter 2025 and full-year 2025 results are forward-looking and subject to risks described in prior annual and quarterly reports.
Senseonics Holdings, Inc. reported an insider equity transaction by its Chief Financial Officer, Frederick T. Sullivan. On 11/15/2025, 6,402 shares of common stock were disposed of at a price of $6.26 per share in a transaction coded "F," which indicates shares were withheld to cover tax obligations on vesting restricted stock units. After this tax withholding, Sullivan beneficially owned 150,626 shares of Senseonics common stock in direct ownership. This type of transaction reflects administrative share withholding rather than an open-market sale.